Press releases & announcements
1 August, 2018
RhoVac AB (“RhoVac”) reported today, August 1, 2018, positive top-line results on safety and on immune activation in their phase I/II clinical trial RhoVac-001 in prostate cancer patients. In totally... [Read more]
9 July, 2018
In 2015, RhoVac AB (“RhoVac”) launched a focused three-year plan aimed at developing the company’s drug candidate RV001, an immuno-oncology treatment, with the potential to prevent or limit the spread... [Read more]
19 June, 2018
RhoVac’s reports positive and constructive response from the European Medicines Agency in the now completed Scientific Advice Procedure
RhoVac AB (“RhoVac”) announced today, June 19, 2018, that the company has received response from the European Medicines Agency (EMA) on the Scientific Advice Procedure. EMA has stated that there... [Read more]
RhoVac in Brief
RhoVac undertakes research and development of therapeutic cancer vaccines. The primary candidate, RV001, targets RhoC which is overexpressed in cancer cells with metastatic potential.
Because most cancers form metastases, RV001 can potentially be used to treat a broad range of cancers. RhoVac's concept focuses on eliminating metastatic cancer cells that may escape treatment of the parent tumour via other methods. Because RhoC is not expressed in the parent tumour, the company goal is to use the developed product in combination with another therapy -- specifically, treatment of the parent tumour by e.g. surgery, radiotherapy or chemotherapy together with treatment with the therapeutic cancer vaccine to combat metastasis.